{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T10:41:57Z","timestamp":1756809717691},"reference-count":13,"publisher":"National Library of Serbia","issue":"9-10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med pregl","MED PREGLED"],"published-print":{"date-parts":[[2009]]},"abstract":"<jats:p>Convincing evidence of the decline of mortality has been achieved with beta-blockers in patients with an acute myocardial infarction and in post-infarction follow-up. The beta-blockers are also the most efficient antianginal medications for the decrease of ischemia in outpatients. They are highly efficient as a monotherapy for angina and are also a medication of choice for angina after the coronary. The objective of this work was an estimate of the use of beta-blockers in secondary prevention of the ischemic heart disease and eliminating doubts concerning their prescription. The method of the analysis sums up the results of a twenty-five- year study on of the outcome of the treatment with beta-blockers in secondary prevention of the ischemic heart disease. The method of the work implies an examination of the professional literature and the data-bases, such as MEDLINE, PubMed and KOBSON. The first studies concerned non-selective beta-blockers, used orally. The following studies concerned cardioselective beta-blockers, metoprolol and atenolol. Several studies followed also the effect of beta-blockers and heparin, or beta-blockers and antagonists of calcium towards placebo, in patients with an unstable angina pectoris. Beta-blockers are an essential drug in secondary prevention of the myocardial infarction and in chronic heart failure. The necessary condition for the efficiency of beta-blockers is an early use. Beta-blockers should be given within 12 hours after the appearance of pain. The continuation of the therapy with beta-blockers after the acute phase is considered to be important in the decrease of the infarction zone expansion. Prophylactic use of beta-blockers after the coronary has an excellent effect, above all in patients with a minor, uncomplicated coronary. Though certain groups of beta-blockers have some special characteristics, when it comes to the treatment of angina pectoris, all beta-blockers are efficient. Generally, patients react well to them. Preference is given to cardioselective remedies, in patients with diabetes or lung disease. Exhaustive controlled clinical studies affirm beta-blockers as drugs that reduce mortality in secondary prevention of the ischemic heart disease.<\/jats:p>","DOI":"10.2298\/mpns0910450r","type":"journal-article","created":{"date-parts":[[2010,2,25]],"date-time":"2010-02-25T08:21:15Z","timestamp":1267086075000},"page":"450-455","source":"Crossref","is-referenced-by-count":2,"title":["Studies of the outcome of the treatment with beta-blockers in secondary prevention of the ischemic heart disease"],"prefix":"10.2298","volume":"62","author":[{"suffix":"V.","given":"Vesna","family":"Radovic","sequence":"first","affiliation":[{"name":"Institut 'Hemofarm', Hemofarm A.D., Beograd"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1078","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(99)00735-3"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.247.12.1707"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(90)90286-A"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(86)80250-9"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(96)00489-5"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(81)91101-6"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03653-9"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.11.1383"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(98)00279-4"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808203390801"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(87)90494-2"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(76)90293-9"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.260.15.2259"}],"container-title":["Medicinski pregled","Medical review"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T09:21:41Z","timestamp":1685352101000},"score":1,"resource":{"primary":{"URL":"https:\/\/doiserbia.nb.rs\/Article.aspx?ID=0025-81050910450R"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009]]},"references-count":13,"journal-issue":{"issue":"9-10","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.2298\/mpns0910450r","relation":{},"ISSN":["0025-8105","1820-7383"],"issn-type":[{"value":"0025-8105","type":"print"},{"value":"1820-7383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009]]}}}